Natural biocon (India) Limited has announced its unaudited financial results for the third quarter ended December 31, 2025, revealing a challenging operational period with zero revenue generation. The Board of Directors approved these results during their meeting held on February 13, 2026.

Financial Performance Overview

The company's Q3FY26 performance showed a stark contrast to the previous year's corresponding quarter. Key financial metrics demonstrate the operational challenges faced during this period.

Quarterly Operational Analysis

The third quarter of FY26 witnessed complete absence of operational revenue, with the company recording zero income from operations. This represents a significant departure from the ₹127.73 lakhs revenue generated in Q3FY25. Despite the revenue decline, the company maintained minimal operational expenses totaling ₹4.27 lakhs.

Expense management during the quarter included employee benefits expense of ₹1.23 lakhs, other expenditure of ₹2.94 lakhs, and depreciation of ₹0.10 lakhs. The company reported no financial costs, material consumption, or stock-in-trade purchases during this period.

Nine-Month Performance Comparison

The year-to-date figures for the nine months ended December 31, 2025, provide additional context to the company's performance trajectory.

For the nine-month period, Natural Biocon achieved revenue of ₹166.57 lakhs compared to ₹601.42 lakhs in the corresponding period of FY25. The company managed to maintain profitability with a net profit of ₹5.23 lakhs, though this represents a substantial decline from the ₹44.83 lakhs profit recorded in the previous year.

Corporate Governance and Compliance

The financial results were reviewed by the Audit Committee and approved by the Board of Directors during their meeting on February 13, 2026. The results have been prepared in accordance with Indian Accounting Standards specified under Section 133 of the Companies Act, 2013, and comply with Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Mayur Shah & Associates, Chartered Accountants, conducted the limited review of these unaudited financial results. The company maintains a paid-up equity share capital of ₹2,578.28 lakhs with a face value of ₹10 per share, which remained unchanged throughout the reporting periods.

Key Financial Highlights

• Zero operational revenue in Q3FY26 versus ₹127.73 lakhs in Q3FY25
• Net loss of ₹4.27 lakhs in Q3FY26 compared to profit of ₹24.59 lakhs in Q3FY25
• Nine-month revenue declined 72.30% to ₹166.57 lakhs
• Earnings per share turned negative at ₹(0.02) for Q3FY26
• Company operates in a single business segment

The results indicate Natural Biocon faced significant operational challenges during the third quarter, with the absence of revenue generation leading to losses despite controlled expense management.

Natural Biocon Limited, a company operating in a single segment, has reported its financial results for the second quarter ended September 30, 2025. The company's performance shows a significant decline in revenue and a shift to loss compared to the previous year.

Financial Highlights

Revenue and Profitability

Natural Biocon reported zero net sales for the quarter ended September 30, 2025, compared to Rs 473.69 lakhs in the same quarter of the previous year. This complete halt in revenue generation is a significant concern.

The company reported a net loss of Rs 4.37 lakhs for the quarter, compared to a profit of Rs 20.24 lakhs in the same quarter last year. This shift from profit to loss is primarily attributed to the absence of revenue during the period.

Half-Year Performance

For the half-year ended September 30, 2025, Natural Biocon reported a profit of Rs 9.49 lakhs, lower than the Rs 29.99 lakhs profit in the corresponding period of the previous year. The half-yearly revenue stood at Rs 166.57 lakhs, showing a substantial decline from Rs 572.34 lakhs in the previous year's corresponding period.

Outlook and Challenges

The complete absence of revenue in Q2 FY2026 raises questions about Natural Biocon's operational status. The company's ability to generate revenue in the coming quarters will be crucial for its financial health and market position.

While the company has maintained a profit for the half-year period despite the challenging second quarter, the sustainability of this performance in light of the revenue decline is a concern. Investors and stakeholders may seek clarity on the factors leading to this situation and the company's strategies to address these challenges.

As Natural Biocon navigates through this period, stakeholders will be watching for any signs of operational revival and return to revenue generation in the subsequent quarters.